Search Results
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
PIM1 kinase inhibitor, being researched for the treatment of relapsed or refractory myelofibrosis (MF), at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: Sumitomo Pharma America
Dec 08, 2025, 10:30 ET Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition
leukemia (CMML) or acute myeloid leukemia (AML). Data from the studies will be shared in two oral presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held on December 6-9, 2025, in Orlando, Florida. Collectively, new data from 15 company-sponsored and company-funded
More news about: Taiho Oncology
Dec 08, 2025, 09:06 ET Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
biopharmaceutical company, today presented new clinical data from its Phase 2a study of ofirnoflast (HT-6184) at the 67th American Society of Hematology (ASH) Annual Meeting. The data show that ofirnoflast, a first-in-class oral allosteric NEK7 inhibitor, induces clinically meaningful and sustained hematologic
More news about: Halia Therapeutics
Dec 08, 2025, 08:00 ET Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
2025 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc., today announced updated results presented at the 67th American Society of Hematology (ASH) Annual Meeting of the pivotal Phase 3
More news about: Pierre Fabre Pharmaceuticals
Dec 08, 2025, 07:50 ET TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
controlling the immunosuppressive capabilities of MDSCs was presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition that took place on Sunday, December 7 in Orlando, FL. The Company presented these updated results, along with a poster
More news about: TuHURA Biosciences, Inc.
Dec 08, 2025, 07:30 ET Recordati Rare Diseases Showcases Real-World Evidence Studies That Advance Understanding of Castleman Disease (CD) at the American Society of Hematology (ASH) Annual Meeting
that can be potentially life-threatening. In a series of poster presentations at the 67th American Society of Hematology Annual Meeting (ASH) Annual Meeting in Orlando, Fla., researchers reported on their work to develop an artificial intelligence (AI) model to facilitate grading and diagnosis
More news about: Recordati
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
SIRPα-Fc fusion protein, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the 67th Annual Meeting of the American Society of Hematology (ASH), held December 6-9, 2025, in Orlando, Florida.
More news about: HanchorBio Inc.
Dec 07, 2025, 22:54 ET 【直擊2025 ASH】亞盛醫藥Bcl-2抑制劑利生妥®治療維奈克拉經治髓系腫瘤患者的Ib/II期研究數據積極，全球競爭力持續顯現
More news about: 亞盛醫藥
Dec 07, 2025, 21:08 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory
More news about: CARsgen Therapeutics
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation
More news about: Leads Biolabs
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple myeloma (NDMM) at the 2025 American Society of Hematology (ASH) Annual Meeting. The data demonstrate that Eque-cel can provide deep and durable responses while maintaining a manageable safety profile for this patient
More news about: IASO Bio
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
(BCMA), and CD3 for the treatment of relapsed or refractory multiple myeloma (R/R MM), in an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. IBI3003 demonstrated favorable tolerability and a manageable safety profile. Despite the relatively short follow-up duration, IBI3003
More news about: Innovent Biologics
Dec 07, 2025, 19:15 ET CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory
More news about: CARsgen Therapeutics
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
treatment-naïve patients, the subgroup with the longest follow-up.These data will be highlighted at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida and simultaneously published in the Journal of Clinical Oncology. "These
More news about: Eli Lilly and Company
Dec 07, 2025, 12:01 ET Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
New England Journal of Medicine (NEJM) and presented simultaneously at the American Society of Hematology (ASH) Annual Meeting, the data reaffirm HEMGENIX's consistent performance over time to deliver durable factor IX activity levels, sustained bleed protection
More news about: CSL
Dec 07, 2025, 09:30 ET Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
myelodysplastic syndrome (MDS). The data are being presented today in an oral session by Dr. Guillermo Garcia-Manero at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 6-9, in Orlando, Florida and virtually. "New therapies are needed for patients with transfusion
More news about: Rigel Pharmaceuticals, Inc.
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
cell or BCMA-related diseases at the 67th American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida from December 6-9, 2025. "The preclinical data presented at this year's ASH Annual Meeting further highlights our potent, non-viral, transient, tunable, and scalable
More news about: Orna Therapeutics
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
decades as a mainstay of treatment for individuals living with blood cancers, according to studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.
More news about: American Society of Hematology
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The presentation, titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable
More news about: Vivacta Biotechnology Co., Ltd.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
#94) were featured in oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting."These data suggest that a single infusion of CARVYKTI for standard-risk patients may provide additional benefit to patients as
More news about: Johnson & Johnson
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
Fla., Dec. 6, 2025 /PRNewswire/ -- Four clinical trials to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition illustrate how advancements in technology are contributing to an improved outlook for many patients with blood cancers.
More news about: American Society of Hematology
Dec 06, 2025, 07:15 ET Studies Highlight Innovative Approaches to Improving Patient Care and Outcomes
ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Four studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition spotlight how re-examining existing practices can illuminate new approaches, or the need for new approaches, to improving
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
episodes of severe pain, known as vaso-occlusive crises. ASH and NHLBI guidelines recommend that patients experiencing vaso-occlusive crises receive opioid pain medication within 60 minutes of arrival at a hospital ED. After the initial dose, ASH guidelines recommend evaluating the patient's pain level
More news about: American Society of Hematology
Dec 05, 2025, 19:55 ET 微芯生物魯先平博士榮獲2025年度安永企業家中國內地大獎
全激動劑西格列他鈉。魯先平博士積極推動中國創新藥審評、醫保准入制度的完善和資本市場的改革，以堅定的拓荒精神、科學追求與對制度創新的深度參與，為中國醫藥產業的發展貢獻了極具分量的「微芯樣本」，展現了以科學為基石、以患者為中心的企業家精神。在魯先平博士的帶領下，微芯生物通過 AI 輔助設計 + 化學基因組學整合式技術平台，構建具有全球競爭力的產品管線，致力於用中國智慧，解世界難題。2025 年，西達本胺共有 47 項成果在 ASCO 、 ESMO 、 EHA 、 ASH 等國際權威學術舞台亮相；西格列他鈉單藥治療代謝相關脂肪性肝炎的 II 期臨床試驗結果在國際肝病領域頂級期刊《 Hepatology 》發表，其研發歷程刊載於國際權威出版社 Elsevier 打造的《 Drug Discovery Stories 》一書。「安永企業家獎」是全球最具影響力的國際商業獎項之一，自
More news about: 深圳微芯生物科技股份有限公司